Vilnius

• Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended recruitment
  2024-514404-13-00 5 2020-10-01 Atopic Dermatitis
• A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed … Ended recruitment
  2022-502746-27-00 5 2020-08-21 Endometrial Cancer
• Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended recruitment
  2023-505830-89-00 6 2020-08-05 metastatic castrate resistant prostate cancer (mCRPC)
• Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended recruitment
  2023-507419-37-00 5 2020-06-25 Plasma cell myeloma
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell … Ended recruitment
  2023-503591-25-00 5 2020-06-09 Non-small cell lung cancer
• Parent and/or Legal Guardian ICF and Adult patient ICF: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study wi … Ended recruitment
  2022-501012-34-00 5 2020-02-27 Pulmonary Arterial Hypertension
• Research study to look at how well the drug Concizumab works in your body if you have haemophilia without inhibitors Ended recruitment
  2023-506831-13-00 5 2020-01-15 haemophilia A (HA) without inhibitors and haemophilia B (HB) without i
• ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2024-515156-21-00 5 2020-01-09 Ulcerative Colitis
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended recruitment
  2023-505495-30-00 5 2019-02-01 Immunoglobulin A Nephropathy (IgAN)
• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended recruitment
  2023-507906-15-00 5 2019-01-30 Relapsing multiple sclerosis (RMS)
• A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter … Ended recruitment
  2022-501485-22-00 5 2018-12-18 Myelodysplastic syndrome (MDS)
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended recruitment
  2023-506994-36-00 5 2018-10-11 Ulcerative Colitis
• A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small- … Ended recruitment
  2024-515755-37-00 4 2018-07-31 Limited disease small-cell lung cancer
• Research study to evaluate the experimental drug ferumoxytol, to see how well it works for children with chronic kidney disease (CKD) and ir … Ended recruitment
  2024-516263-92-00 5 2018-06-25 Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney
• Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended recruitment
  2023-504820-24-00 5 2018-03-21 Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
• A study to investigate the clinical benefit of isatuximab in combination with bortezomib, lenalidomide and dexamethasone in adults with newl … Ended recruitment
  2024-514417-34-00 5 2017-12-14 Cancer
• A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea … Ended recruitment
  2023-506399-28-00 5 2017-11-08 Crohn's Disease
• A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comple … Ended recruitment
  2023-504951-29-00 5 2017-07-27 Chron's Disease
• A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended recruitment
  2024-517321-99-00 4 2016-08-01 Myeloma multiplex
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth … Ended recruitment
  2022-501017-31-00 5 2016-05-10 Rheumatoid arthritis
• A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi … Ended recruitment
  2023-509348-84-00 5 2015-04-27 Chronic Lymphocytic Leukemia
• Phase 2 Study of ALXN2420 versus Placebo in Combination with Somatostatin Analogs in Participants with Acromegaly Halted
  2025-521243-20-00 4 2025-10-23 Acromegaly

Showing 121–144 of 186 trials